Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksADAM.L Regulatory News (ADAM)

  • There is currently no data for ADAM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Final Results

29 Jun 2017 10:45

RNS Number : 5767J
Adamas Finance Asia Limited
29 June 2017
 

Adamas Finance Asia Limited

("Adamas Finance Asia", "ADAM" or the "Company")

 

Final Results for the year ended 31 December 2016

 

Highlights:

 

· 125% increase in dividend and interest income received to US$911,000 (2015: US$404,000)

 

· Operating expenses down 16% to US$1.9 million (2015: US$2.3 million)

 

· Loss for the year of US$37.2 million as a result of write-downs in the value of legacy assets (2015: US$3.8 million)

 

· Year-end cash of US$1.3 million (2015: US$3.6 million)

 

· Consolidated net asset value at 31 December 2016 of US$77.8 million (2015: US$115.1 million)

 

· Consolidated net asset value per share at 31 December 2016 of 40.5c per share (2015: 59.9c)

 

· Post year-end cash receipts totaling US$15.6 million

 

· Intention to introduce dividend payments in due course

 

Adamas Finance Asia Chairman John Croft commented: "Overall, 2016 was a disappointing year in terms of financial results, driven primarily by impairments in the Company's asset portfolio. However, recent developments, including the appointment of a new Investment Manager along with a broadening of the Investing Policy approved by shareholders in May 2017, has provided us with a much firmer and more positive platform from which to grow the business. Significantly, since the year end, the Company has also received cash totaling US$15.6 million resulting from the disposal of its investment in the Tian Tong Shan Villa Project and a distribution from its investment in the Greater China Credit Fund. That cash is now available to invest in line with the revised Investing Policy.  We also hope to be making announcements in the near future regarding new appointments to strengthen the Board in preparation for the next phase of the Company's development. Finally, it is important to note that it remains the Board's intention to start making dividend distributions as soon as is practical."

 

Enquiries:

 

Adamas Finance Asia Limited

John Croft

+44 (0) 1825 830587

WH Ireland Limited - Nominated Adviser

Tim Feather

Ed Allsopp

+44 (0) 113 394 6600

+44 (0) 117 945 3444

finnCap Limited - Broker

William Marle

Grant Bergman

+44 (0) 20 7220 0500

First City Public Relations (Hong Kong)

+852 2854 2666

Allan Piper

+44 (0) 7438 148968

 

 

CHAIRMAN'S STATEMENT

 

Events during the year to 31 December 2016 showed once again that investments made by the Group continued to produce cash in line with the Group's long-term income-generation strategy. At the same time, ongoing setbacks to the planned disposal of its legacy assets meant the Group during the year remained without the large cash holdings needed to bolster its investment programme.

 

Encouragingly, that picture has started to change significantly within the past few weeks, with the arrival of US$15.6 million in cash, comprising US$15.1 million in near-complete payment for the Company's disposal of Changtai Jinhongbang Real Estate Development Co. Ltd ("CJRE"), announced in January 2017. The decision to dispose of CJRE was taken by the Board as an opportunity to exit this investment arose albeit at a significant book value loss. The Board decided that it was preferable to have immediate cash to reinvest in income generating assets, rather than retain a 15% holding in an asset which was illiquid and could take many years to realise a successful exit. Additionally a distribution of US$500,000 was received from the Greater China Credit Fund ("GCCF").  During the year, income from existing investments rose 125% to US$911,000 (2015: US$404,000), while administrative expenses were trimmed by 16% to US$1.9 million (2015: US$2.3 million).

 

While existing income-generating assets yielded healthy returns over the course of the year, the Group also received US$840,000 from the redemption of its original US$800,000 holding in the BRJ Fund, along with a capital redemption of US$700,000 from GCCF, plus interest of US$120,000. The Group continues to hold a stake of approximately US$2.7 million in GCCF.

 

The loss for the year was US$37.2 million (2015: US$3.8 million) which was due primarily to write-downs in the value of the Group's legacy assets totaling US$36.3 million. The substantial majority of the write-downs related to the Group's interest in the Tian Tong Shan Villa Project, the proposed sale of which was announced on 4 January 2017. Further details on the write-downs are set out below.

 

The significant loss demonstrates the difficulties arising from the Group's ownership of its legacy assets. On the one hand the Group is able to identify solid income-generating investments with realisable exits. Yet at the same time, it continues to face difficulties in achieving value for its older legacy assets so that the resulting cash can be deployed into income-generating opportunities.

 

In the light of the past disappointments experienced by the Group and a desire to focus on broader investment opportunities away from predominantly China, the Board sought Shareholder approval for a broadening of the Investing Policy. As a result, the Group is now positioned to take advantage of a wider range of investment opportunities not only more broadly across Asia, but also across the capital structure of investment targets. The details of the new Investing Policy were announced on 2 May 2017, and are designed to allow the Group's Investment Manager to navigate changes in the relative attractiveness of various financing asset classes.

 

The Group also announced the appointment of a new independent Investment Manager, Harmony Capital Investors Limited ("Harmony"). Harmony brings wide Asian experience and a strong team with proven success in identifying and managing high-return opportunities across a wide range of Asian asset classes, and I believe the Group is now more strongly positioned than ever before to move forward successfully.

 

The principal investment assets held by the Group at the year-end, together with their valuations, were:

Portfolio at 31 December 2016

Core Assets

Effective Interest

Instrument type

Valuation as at 31 December 2016

US$ million

Changtai Jinhongbang Real Estate Development Co. Ltd

15.00%

Structured equity

16.4

Global Pharm Holdings Group Inc

-

Redeemable convertible bond

17.3

Fortel Technology / I-Buying Loan

-

Interest bearing loan

11.3

Hong Kong Mining Holdings Limited

10.95%

Structured equity

8.8

Meize Energy Industrial Holdings Ltd

7.9%

Redeemable convertible preference shares

8.2

GCCF

Investment Fund

2.7

Other investments

11.9

Cash

1.3

Total net book value

77.9

 

Changtai Jinhongbang Real Estate Development Co. Ltd ("CJRE") is the owner of the Tian Tong Shan Villa Project, a luxury resort and residential development in Xiamen, Eastern China. Sales of villas and serviced apartments have been very slow and consequently the Board took the decision to dispose of this asset as otherwise realisation of the Group's investment could have taken many years to materialise. The sale proceeds have required the Group to recognise an impairment equivalent to US$32 million at 31 December 2016, but has, subsequent to the year end, generated cash that may now be reinvested and thereby start to generate income.

 

Cash from the disposal process totaling US$15.1 million has now been received, with the remaining balance of US$1.7 million being converted into a two-year, zero coupon loan to the purchaser.

Global Pharm Holdings Group Inc. ("Global Pharm") is involved in pharmaceuticals, the cultivation of herbs for Traditional Chinese Medicine ("TCM") and TCM processing and distribution. As announced previously, Global Pharm did not meet the original redemption payment plan agreed in December 2014. Global Pharm has been investing in the planned launch of an online Ginseng Exchange in Jilin Province. This resulted in its cash flow being adversely impacted as it invested in building a stockpile of ginseng in readiness for the launch of the exchange. In view of the continuing delays in receipt of payments from Global Pharm, the Directors have decided to make an impairment, amounting to US$1.9 million in the 2016 accounts equivalent to 10% of the previous US$19.2 million carrying value. The Directors remain hopeful that a full recovery of the outstanding payments may be obtained and are working closely with the Investment Manager to ensure this is achieved.

Fortel Technology Holdings Limited ("Fortel") During 2016 the Group agreed to convert its equity holding in Fortel to an interest-bearing loan in order to facilitate the IPO for its Chinese subsidiary on the NEEQ exchange in Beijing. The conversion was completed in October 2016.

Hong Kong Mining Holdings Limited ("HKMH") is a resources company whose primary asset is a large dolomite magnesium limestone mine in the province of Shanxi, China. HKMH's application to list on the Hong Kong Exchange was rejected by the exchange as previously announced. ADAM's Investment Manager is exploring various alternatives for restructuring this asset and/or seeking buyers for its stake.

Meize Energy Industries Holdings Limited ("Meize") is a privately-owned company that designs and manufactures blades for wind turbines. It has a strong order book and its financial performance has been in line with expectations.  Negotiations regarding the partial sale and restructuring of this investment are ongoing.

 

The recent cash receipts totaling US$15.6 million have, as at 28 June 2017, altered the year-end asset valuation only slightly, but have also, more significantly, transformed the Company's ability to look seriously at new income-generation investment opportunities across Asia.

 

Portfolio at 28 June 2017 (unaudited)

 

Core Assets

Effective Interest

Instrument type

Valuation as at 28 June 2017

US$ million

Global Pharm Holdings Group Inc

-

Redeemable convertible bond

17.3

Fortel Technology / I-Buying Loan

-

Interest bearing loan

11.6

Hong Kong Mining Holdings Limited

10.95%

Structured equity

8.8

Meize Energy Industrial Holdings Ltd

7.9%

Redeemable convertible preference shares

8.2

 

GCCF

Investment Fund

2.7

Other investments

14.8

Cash

15.1

Total net book value

78.5

 

 

John Croft

Chairman of the Board

28 June 2017

 

 

Consolidated Statement of Comprehensive Income

For the year ended 31 December 2016

 

2016

2015

US$'000

US$'000

Realised gain on disposal of investments

5

-

Fair value changes on financial assets at fair value through profit or loss

(34,094)

 

(2,265)

 

 

Loan written off

(2,238)

Administrative expenses

(1,948)

(2,306)

Operating loss

(38,275)

(4,571)

Finance income

 80

467

Finance expense

 (98)

(216)

Dividend income

 911

404

Other income

 220

-

Loss before taxation

(37,162)

(3,916)

Taxation

-

-

Loss for the year

(37,162)

(3,916)

Other comprehensive expense:

Items that will or may be reclassified to profit or loss:

Exchange differences arising on translation of foreign operations

-

-

Total comprehensive expense for the year

(37,162)

(3,916)

Loss per share

Basic

19.36 cents

2.02 cents

Diluted

19.36 cents

2.02 cents

 

The results reflected above relate to continuing operations.

 

 

 

 

Consolidated Statement of Changes in Equity

For the year ended 31 December 2016

 

Share capital

Share based payment reserve

Foreign translation reserve

Accumulated losses

Total

US$'000

US$'000

US$'000

US$'000

US$'000

Group balance at 1 January 2016

129,528

42

-

-10,717

118,853

Loss for the year

-

-

-

-3,916

-3,916

Other comprehensive income

Exchange differences arising on translation of foreign operations

 

 

-

 

 

-

 

 

-

 

 

-

 

 

-

Total comprehensive expense for the year

-

-

-

(3,916)

(3,916)

Issue of shares

15

-

-

-

15

Share-based payments

-

(41)

-

41

-

Group balance at 31 December 2015 and 1 January 2016

129,543

1

-

(14,592)

114,952

Loss for the year

 -

 -

 -

(37,162)

(37,162)

Other comprehensive income

Exchange differences arising on translation of foreign operations

-

-

-

-

-

Total comprehensive expense for the year

 129,543

 1

 -

(51,754)

77,790

Issue of shares

-

-

-

-

-

Share-based payments

-

(1)

-

-

(1)

Group balance at 31 December 2016

 129,543

 -

 -

(51,754)

77,789

 

 

 

Consolidated Statement of Financial Position

As at 31 December 2016

 

2016

2015

US$'000

US$'000

Assets

Unquoted financial assets at fair value through profit or loss

75,044

110,593

Loans and other receivables

 1,514

3,496

Cash and cash equivalents

 1,308

3,644

Total assets

77,866

117,733

Liabilities

Loan payables and interest payables

-

2,518

Other payables and accruals

77

263

Total liabilities

77

2,781

Net assets

77,789

114,952

Equity and reserves

Share capital

129,543

129,543

Share based payment reserve

-

1

Accumulated losses

(51,754)

(14,592)

Total equity and reserves attributable to owners of the parent

77,789

114,952

 

 

Consolidated Cash Flow Statement

For the year ended 31 December 2016

 

2016

2015

US$'000

US$'000

Cash flows from operating activities

Loss before taxation

(37,162)

(3,916)

Adjustments for :

Depreciation

-

-

Dividend income

(911)

(404)

Finance income

(80)

(467)

Finance expense

98

216

Loan written off

2,238

-

Fair value changes on unquoted financial assets at fair value through profit or loss

34,094

2,265

Fair value changes on quoted financial assets at fair value through profit or loss

-

-

Realised gain on disposal of investments

(5)

-

Share-based expenses

(1)

-

(Increase) / Decrease in other receivables

(12)

431

Increase / (Decrease) in other payables and accruals

(186)

79

Net cash used in operating activities

(1,927)

(1,796)

Cash flows from investing activities

Dividend income received

1,611

324

Sale proceeds of quoted financial assets at fair value through profit or loss

756

-

Purchase of unquoted financial assets at fair value through profit or loss

(2,560)

(440)

Loans granted

(655)

Proceeds from repayment of loan granted

2,400

5,813

Net cash used in investing activities

2,207

5,042

Cash flows from financing activities

Finance expense paid

(216)

(109)

Loans repaid

(2,400)

-

Net proceeds from issue of shares

-

15

Net cash generated from financing activities

(2,616)

(94)

Net increase / (decrease) in cash and cash equivalents

(2,336)

3,152

Cash and cash equivalent at the beginning of the year

3,644

492

Cash and cash equivalent at the end of the year

1,308

3,644

 

 

Notes to the Financial Statements

For the year ended 31 December 2016

 

1. Board Approval and 2016 Annual Report and Financial Statements

 

The financial information included in this report has been extracted from the Group Financial Statements for the year ended 31 December 2016 which were approved by the Board of Directors on 28 June 2017. The Group Financial Statements have been prepared in accordance with the accounting policies set out therein and in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board.

 

The auditors have reported on the 2016 Financial Statements and their report is unqualified. The information included does not constitute the Company's statutory accounts. The full financial statements will be included in the Group's annual report.

 

The annual report will be posted to shareholders on 30 June 2017 and be available from the Company's website at www.adamasfinance.com from 30 June 2017.

 

 

2. Unquoted financial assets at fair value through profit and loss

 

Group

Company

US$'000

US$'000

Balance as at 1 January 2015

117,576

117,576

Fair value changes through profit or loss

(2,265)

(2,265)

Additions

1,097

1,097

Disposals

(5,815)

(5,815)

Balance as at 1 January 2016

110,593

110,593

Fair value changes through profit or loss

 (34,094)

 (34,094)

Additions

 2,480

 2,480

Disposals

 (3,935)

 (3,935)

Balance as at 31 December 2016

 75,044

 75,044

 

 

3. Loss per Share

 

The calculation of the basic and diluted loss per share attributable to the ordinary equity holders of the Group is based on the following:

 

2016

2015

US$'000

US$'000

Numerator

Basic/Diluted :

Net loss

(37,162)

(3,916)

No. of shares

No. of shares

'000

'000

Denominator

Basic:

Weighted average shares

191,967

191,963

Effect of diluted securities:

Share options

-

150

Warrant

-

-

Diluted:

Adjusted weighted average shares

191,967

192,113

 

For the year ended 31 December 2016 and 2015, the share options are anti-dilutive and therefore the weighted average shares in issue are 191,967,000 and 191,963,000 respectively.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FR OKCDNCBKKNAB
Date   Source Headline
13th Jan 20215:23 pmRNSSEDOL Code Update
13th Jan 20217:00 amRNSConfirmation of Change of Company Name
11th Jan 20215:17 pmRNSDirector Dealings
31st Dec 202011:00 amRNSPlacing Update
14th Dec 20208:08 amRNSChange of Auditor
10th Dec 202010:17 amRNSAppointment of new Broker
1st Dec 202011:52 amRNSDirectors Dealings
19th Nov 20207:00 amRNSUnaudited NAV and Portfolio Update for Q3 30 Sept
2nd Nov 202012:21 pmRNSPlacing Update
16th Oct 20203:57 pmRNSHolding(s) in Company
16th Oct 20203:57 pmRNSHolding(s) in Company
16th Oct 20203:55 pmRNSHolding(s) in Company
16th Oct 20203:53 pmRNSHolding(s) in Company
9th Oct 20202:49 pmRNSHolding(s) in Company
7th Oct 20207:00 amRNSResult of Open Offer & Placing & Share Allotment
1st Oct 20207:00 amRNSOpen Offer and Placing Update and Portfolio Update
22nd Sep 20202:12 pmRNSShare Buyback
18th Sep 20204:14 pmRNSOpen Offer and Placing Update
10th Sep 20205:23 pmRNSOpen Offer and Placing Update
7th Sep 20203:10 pmRNSShare Buyback
7th Sep 20207:00 amRNSOpen Offer and Placing Update
2nd Sep 20203:32 pmRNSOpen Offer and Placing Update
28th Aug 20207:00 amRNSAsset Overview: FLMH
24th Aug 20207:00 amRNSResult of Open Offer
21st Aug 20208:50 amRNSInterim Results for the six months ended 30 Jun 20
20th Aug 20201:39 pmRNSHolding(s) in Company
20th Aug 20201:38 pmRNSHolding(s) in Company
19th Aug 20207:00 amRNSAppointment of Non-Executive Director
18th Aug 20208:51 amRNSShare Buyback Programme
17th Aug 20207:22 amRNSResult of 2020 AGM
17th Aug 20207:20 amRNSResult of 2019 AGM
12th Aug 20208:26 amRNSAsset Overview: Meize Energy
7th Aug 20207:00 amRNSUpdate on Future Metal Holdings
5th Aug 20203:07 pmRNSResult of General Meeting
5th Aug 20207:00 amRNSFuture Metal Holdings Limited: Asset Overview
22nd Jul 20207:00 amRNSNotice of 2019 and 2020 Annual General Meetings
20th Jul 202010:26 amRNSHolding(s) in Company
17th Jul 20207:00 amRNSOpen Offer, Placing and Notice of GM
3rd Jul 20209:09 amRNSUpdate on Future Metal Holdings Limited
9th Jun 20204:00 pmRNSAGM Update
3rd Jun 20207:00 amRNSUnaudited Net Asset Value and Portfolio Update
1st Jun 20207:58 amRNSResearch Note and Interview Published
18th May 20207:00 amRNSFinal Results
11th May 20207:00 amRNSSecond Subscription to Corporate Bond
3rd Mar 20202:09 pmRNSPlacing of Shares with a Syndicate
5th Feb 20207:00 amRNSResearch Note and Interview Published
27th Dec 20197:00 amRNSFuture Metal: Production Commenced and Update
23rd Dec 20197:00 amRNSShare Buyback
15th Nov 20197:00 amRNSCompletion of SPA with Infinity Capital Group
14th Nov 20196:24 pmRNSPostponement of Annual General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.